Dr. Reddy's Laboratories Ltd (RDY) 53.85 $RDY
Dr. Reddy's to acquire product portfolio from TEVA for US Market
BusinessWire - Sat Jun 11, 8:26AM CDT
Dr. Reddy's Laboratories (BSE:500124, NSE
RREDDY, NYSE:RDY) has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and an affiliate of Allergan plc (NYSE:AGN)to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the U.S. for $350 million in cash at closing. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business. The acquisition of these ANDAs is also contingent on the closing of the Teva/Allergan generics transaction and approval by the U.S. Federal Trade Commission of Dr. Reddy's as a buyer.
AGN: 239.70 (+1.42), RDY: 53.85 (-0.60)
Promius Pharma Launches Sernivo(TM) (betamethasone dipropionate) Spray, 0.05%
BusinessWire - Wed Jun 01, 1:48AM CDT
Dr. Reddy's Laboratories announced today that its US subsidiary, Promius Pharma, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), launched Sernivo(TM) (betamethasone dipropionate) Spray, 0.05% in the U.S. Sernivo Spray, a prescription topical steroid approved by the Food and Drug Administration (FDA) in February of 2016, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.
RDY: 53.85 (-0.60)
Dr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:57PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) announced that it acquired a portfolio of OTC brands in the cough-and-cold, pain, and dermatology categories from Ducere Pharma.
ABT: 42.47 (+0.35), JNJ: 122.92 (-0.01), RDY: 53.85 (-0.60)
Dr. Reddy's Enters the Branded Consumer Health Arena Through the Acquisition of Six OTC Brands
BusinessWire - Wed May 25, 5:47AM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced the acquisition of an eminent portfolio of over-the-counter (OTC) brands in the cough-and-cold, pain, and dermatology categories. The company acquired six OTC brands from Ducere Pharma, including DOAN'S(R), BUFFERIN(R), NUPERCAINAL(R) Ointment, CRUEX(R) Nail Gel, COMTREX(R), and MYOFLEX(R).
RDY: 53.85 (-0.60)
Dr. Reddy's Q4 and FY16 Financial Results
BusinessWire - Thu May 12, 5:47AM CDT
--Q4 EBITDA at Rs. 4.8 billion(12.8% of the revenues)
RDY: 53.85 (-0.60)
Dr. Reddy's Laboratories Announces the Appointment of Mr. Bharat Doshi as an Additional Independent Director on the Board of the Company
BusinessWire - Wed May 11, 12:14PM CDT
Mr. Bharat Doshi has been appointed as an Additional Independent Director on the Board of Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), effective May 11, 2016.
RDY: 53.85 (-0.60)
Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:03AM CDT
Quite a few companies are still yet to report results. Let's take a peek at a few drug stocks that will report quarterly results later this week
JNJ: 122.92 (-0.01), GILD: 86.63 (+0.38), PFE: 36.24 (+0.09), AMGN: 161.96 (+1.78), ABBV: 65.50 (+1.15), RDY: 53.85 (-0.60), AVXS: 38.94 (+1.91), NVS: 81.68 (-0.63)
Dr. Reddy's to Release Q4 and Full Year FY16 Results on May 12, 2016; Earnings Call Slated for May 12, 6.30 PM IST / 9.00 AM EDT
BusinessWire - Tue Apr 26, 6:34AM CDT
Dr. Reddy's Laboratories (NYSE: RDY; NSE: DRREDDY; BSE: 500124) will announce results for the Fourth Quarter and Full Year ended March 31, 2016 on Thursday, May 12, 2016 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 53.85 (-0.60)
ZEMBRACE(TM) SymTouch(TM) (Sumatriptan Injection) 3 mg, Approved by the FDA in January 2016 for the Acute Treatment of Migraine with or without Aura in Adults, is Now Commercially Available in the U.S.
BusinessWire - Tue Apr 19, 4:12AM CDT
Promius Pharma LLC, a subsidiary of Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced today that ZEMBRACE SymTouchis now commercially available in the U.S.
RDY: 53.85 (-0.60)
Cutispharma, Dr. Reddy's Laboratories Announce Partnership
PR Newswire - Tue Apr 05, 5:00AM CDT
CutisPharma, a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, announced today that it is entering into Active Pharmaceutical Ingredient (API) supply and joint development agreements with Dr. Reddy's Laboratories Ltd. to advance several programs in CutisPharma's R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.
RDY: 53.85 (-0.60)
Dr. Reddy's Acquires Anticancer Drug Rights from Eisai
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 8:40AM CDT
Dr. Reddy's Laboratories (RDY) announced that it has entered into a licensing agreement with Eisai Co., Ltd, Japan.
AMAG: 25.50 (-0.02), RDY: 53.85 (-0.60), XNPT: 7.07 (+0.05)
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories
JCN Newswire - Thu Mar 31, 3:34AM CDT
TOKYO, Mar 31, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has entered into an agreement to transfer the exclusive worldwide development and marketing rights (excluding Japan and Asia) for its investigational anticancer agent E7777 to Dr. Reddy's Laboratories Ltd. (Dr. Reddy's).
RDY: 53.85 (-0.60)
Dr. Reddy's Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S., Europe and Certain Emerging Markets from Eisai
BusinessWire - Thu Mar 31, 3:28AM CDT
Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has entered into a licensing agreement with Eisai Co., Ltd, Japan by which Dr. Reddy's will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai's investigational anticancer agent E7777. Eisai will be responsible for the development and marketing of E7777 in Japan and Asia, while Dr. Reddy's holds the option for rights to develop and market the agent in India.
RDY: 53.85 (-0.60)
Dr Reddy's Collaborates with XenoPort for Psoriasis Drug
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 3:10PM CDT
Dr. Reddy's Laboratories (RDY) announced that it has entered into a license agreement with XenoPort, Inc. (XNPT).
AMAG: 25.50 (-0.02), RDY: 53.85 (-0.60), XNPT: 7.07 (+0.05)
Dr. Reddy's Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829
BusinessWire - Mon Mar 28, 7:30AM CDT
Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc. (NASDAQ: XNPT) announced today that they have entered into a license agreement pursuant to which Dr. Reddy's Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort's clinical-stage oral new chemical entity, XP23829. Dr. Reddy's Laboratories plans to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis and may potentially develop XP23829 for relapsing forms of multiple sclerosis (MS).
RDY: 53.85 (-0.60), XNPT: 7.07 (+0.05)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Dr. Reddy's Laboratories Ltd. and Certain Officers and Directors
BusinessWire - Thu Mar 03, 8:55AM CST
Levi & Korsinsky, LLP announces that it has commenced an investigation of Dr. Reddy's Laboratories Ltd. ("RDY" or the "Company" (NYSE: RDY) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
RDY: 53.85 (-0.60)
Dr. Reddy's Q3 Earnings Up Y/Y, Warning Letter in Focus
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 10:06AM CST
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2016 earnings per American Depositary Share of 51 cents, up 1% from the year-ago quarter.
ATRA: 22.55 (-0.12), BXLT: 46.02 (-0.18), RDY: 53.85 (-0.60)
Dr. Reddy's Q3 and 9M FY16 Financial Results
BusinessWire - Tue Feb 09, 3:55AM CST
--9M Revenues at Rs. 117.1 billion (YoY growth of 7%)9M EBITDA at Rs. 31.4 billion (26.8% of the revenues)
RDY: 53.85 (-0.60)
18.1% Return Seen to Date on SmarTrend Dr Reddys Laboratories Call (RDY)
Comtex SmarTrend(R) - Thu Feb 04, 3:54PM CST
SmarTrend identified a Downtrend for Dr Reddys Laboratories (NYSE:RDY) on November 6th, 2015 at $53.91. In approximately 3 months, Dr Reddys Laboratories has returned 18.06% as of today's recent price of $44.17.
RDY: 53.85 (-0.60)
Dr. Reddy's to acquire product portfolio from TEVA for US Market
BusinessWire - Sat Jun 11, 8:26AM CDT
Dr. Reddy's Laboratories (BSE:500124, NSE
RREDDY, NYSE:RDY) has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and an affiliate of Allergan plc (NYSE:AGN)to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the U.S. for $350 million in cash at closing. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business. The acquisition of these ANDAs is also contingent on the closing of the Teva/Allergan generics transaction and approval by the U.S. Federal Trade Commission of Dr. Reddy's as a buyer. AGN: 239.70 (+1.42), RDY: 53.85 (-0.60)
Promius Pharma Launches Sernivo(TM) (betamethasone dipropionate) Spray, 0.05%
BusinessWire - Wed Jun 01, 1:48AM CDT
Dr. Reddy's Laboratories announced today that its US subsidiary, Promius Pharma, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), launched Sernivo(TM) (betamethasone dipropionate) Spray, 0.05% in the U.S. Sernivo Spray, a prescription topical steroid approved by the Food and Drug Administration (FDA) in February of 2016, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.
RDY: 53.85 (-0.60)
Dr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:57PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) announced that it acquired a portfolio of OTC brands in the cough-and-cold, pain, and dermatology categories from Ducere Pharma.
ABT: 42.47 (+0.35), JNJ: 122.92 (-0.01), RDY: 53.85 (-0.60)
Dr. Reddy's Enters the Branded Consumer Health Arena Through the Acquisition of Six OTC Brands
BusinessWire - Wed May 25, 5:47AM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced the acquisition of an eminent portfolio of over-the-counter (OTC) brands in the cough-and-cold, pain, and dermatology categories. The company acquired six OTC brands from Ducere Pharma, including DOAN'S(R), BUFFERIN(R), NUPERCAINAL(R) Ointment, CRUEX(R) Nail Gel, COMTREX(R), and MYOFLEX(R).
RDY: 53.85 (-0.60)
Dr. Reddy's Q4 and FY16 Financial Results
BusinessWire - Thu May 12, 5:47AM CDT
--Q4 EBITDA at Rs. 4.8 billion(12.8% of the revenues)
RDY: 53.85 (-0.60)
Dr. Reddy's Laboratories Announces the Appointment of Mr. Bharat Doshi as an Additional Independent Director on the Board of the Company
BusinessWire - Wed May 11, 12:14PM CDT
Mr. Bharat Doshi has been appointed as an Additional Independent Director on the Board of Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), effective May 11, 2016.
RDY: 53.85 (-0.60)
Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:03AM CDT
Quite a few companies are still yet to report results. Let's take a peek at a few drug stocks that will report quarterly results later this week
JNJ: 122.92 (-0.01), GILD: 86.63 (+0.38), PFE: 36.24 (+0.09), AMGN: 161.96 (+1.78), ABBV: 65.50 (+1.15), RDY: 53.85 (-0.60), AVXS: 38.94 (+1.91), NVS: 81.68 (-0.63)
Dr. Reddy's to Release Q4 and Full Year FY16 Results on May 12, 2016; Earnings Call Slated for May 12, 6.30 PM IST / 9.00 AM EDT
BusinessWire - Tue Apr 26, 6:34AM CDT
Dr. Reddy's Laboratories (NYSE: RDY; NSE: DRREDDY; BSE: 500124) will announce results for the Fourth Quarter and Full Year ended March 31, 2016 on Thursday, May 12, 2016 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 53.85 (-0.60)
ZEMBRACE(TM) SymTouch(TM) (Sumatriptan Injection) 3 mg, Approved by the FDA in January 2016 for the Acute Treatment of Migraine with or without Aura in Adults, is Now Commercially Available in the U.S.
BusinessWire - Tue Apr 19, 4:12AM CDT
Promius Pharma LLC, a subsidiary of Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced today that ZEMBRACE SymTouchis now commercially available in the U.S.
RDY: 53.85 (-0.60)
Cutispharma, Dr. Reddy's Laboratories Announce Partnership
PR Newswire - Tue Apr 05, 5:00AM CDT
CutisPharma, a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, announced today that it is entering into Active Pharmaceutical Ingredient (API) supply and joint development agreements with Dr. Reddy's Laboratories Ltd. to advance several programs in CutisPharma's R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.
RDY: 53.85 (-0.60)
Dr. Reddy's Acquires Anticancer Drug Rights from Eisai
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 8:40AM CDT
Dr. Reddy's Laboratories (RDY) announced that it has entered into a licensing agreement with Eisai Co., Ltd, Japan.
AMAG: 25.50 (-0.02), RDY: 53.85 (-0.60), XNPT: 7.07 (+0.05)
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories
JCN Newswire - Thu Mar 31, 3:34AM CDT
TOKYO, Mar 31, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has entered into an agreement to transfer the exclusive worldwide development and marketing rights (excluding Japan and Asia) for its investigational anticancer agent E7777 to Dr. Reddy's Laboratories Ltd. (Dr. Reddy's). RDY: 53.85 (-0.60)
Dr. Reddy's Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S., Europe and Certain Emerging Markets from Eisai
BusinessWire - Thu Mar 31, 3:28AM CDT
Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has entered into a licensing agreement with Eisai Co., Ltd, Japan by which Dr. Reddy's will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai's investigational anticancer agent E7777. Eisai will be responsible for the development and marketing of E7777 in Japan and Asia, while Dr. Reddy's holds the option for rights to develop and market the agent in India.
RDY: 53.85 (-0.60)
Dr Reddy's Collaborates with XenoPort for Psoriasis Drug
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 3:10PM CDT
Dr. Reddy's Laboratories (RDY) announced that it has entered into a license agreement with XenoPort, Inc. (XNPT).
AMAG: 25.50 (-0.02), RDY: 53.85 (-0.60), XNPT: 7.07 (+0.05)
Dr. Reddy's Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829
BusinessWire - Mon Mar 28, 7:30AM CDT
Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc. (NASDAQ: XNPT) announced today that they have entered into a license agreement pursuant to which Dr. Reddy's Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort's clinical-stage oral new chemical entity, XP23829. Dr. Reddy's Laboratories plans to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis and may potentially develop XP23829 for relapsing forms of multiple sclerosis (MS).
RDY: 53.85 (-0.60), XNPT: 7.07 (+0.05)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Dr. Reddy's Laboratories Ltd. and Certain Officers and Directors
BusinessWire - Thu Mar 03, 8:55AM CST
Levi & Korsinsky, LLP announces that it has commenced an investigation of Dr. Reddy's Laboratories Ltd. ("RDY" or the "Company"
(NYSE: RDY) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. RDY: 53.85 (-0.60)
Dr. Reddy's Q3 Earnings Up Y/Y, Warning Letter in Focus
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 10:06AM CST
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2016 earnings per American Depositary Share of 51 cents, up 1% from the year-ago quarter.
ATRA: 22.55 (-0.12), BXLT: 46.02 (-0.18), RDY: 53.85 (-0.60)
Dr. Reddy's Q3 and 9M FY16 Financial Results
BusinessWire - Tue Feb 09, 3:55AM CST
--9M Revenues at Rs. 117.1 billion (YoY growth of 7%)9M EBITDA at Rs. 31.4 billion (26.8% of the revenues)
RDY: 53.85 (-0.60)
18.1% Return Seen to Date on SmarTrend Dr Reddys Laboratories Call (RDY)
Comtex SmarTrend(R) - Thu Feb 04, 3:54PM CST
SmarTrend identified a Downtrend for Dr Reddys Laboratories (NYSE:RDY) on November 6th, 2015 at $53.91. In approximately 3 months, Dr Reddys Laboratories has returned 18.06% as of today's recent price of $44.17.
RDY: 53.85 (-0.60)
